Skip to main navigation
AASLD Family of Websites: The Liver Meeting
AASLD.org AASLD Foundation LiverLearning Careers Journals Liver Fellow Network HCV Guidelines
Home

TLM Main Navigation

  • Claim CE Credits
  • For Industry
    Why Exhibit Reserve a Booth Exhibitor Resources
  • Attend
    Housing Venue Visa Letter
  • Program
    Call for Abstracts Open On-Site Guides
  • Submit an Abstract

Clinical Plenary #2

Nov 13 2023
Auditorium - Hynes Convention Center
9:00 - 10:00 AM EST

Speakers

Mary E. McCarthy Rinella

The University of Chicago

Mohit Kumar Varshney

Institute of Liver and Biliary Sciences

Madhumita Premkumar

Postgraduate Institute of Medical Education & Research

Subhojit Paul

UT Southwestern Medical Center

Description

Abstracts

  • RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL.
  • ANALYZING NEW ONSET HEPATIC DECOMPENSATION AND LONG TERM ABSTINENCE/CRAVING IN PATIENTS WITH ALCOHOL ASSOCIATED LIVER DISEASES(AALD): A DOUBLE BLIND RANDOMIZED CONTROL TRIAL (RCT) FOR EFFECTIVENESS OF SELF ADMINISTERED 12 WEEKS 50 MG ORAL NALTREXONE VERSUS PLACEBO; ALONG WITH STANDARD COUNSELLING
  • MOLECULAR SIGNATURES TO PREDICT RISK OF HEPATOCELLULAR CARCINOMA POST HEPATITIS C CURE
  • POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS
About Us
  • AASLD Foundation
  • About AASLD
Legal
  • Abstract Policies
  • Accreditation and Designation Statements
  • Disclosure Policy
  • Embargo Policy
  • Ethics Policy
  • Event Registration Policies
  • Limited License for Use
Get In Touch
  • Contact
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Copyright © 2025 American Association for the Study of Liver Diseases
AASLD: The Liver Meetings - Nov. 15-19, 2024